| Phase 13 trials |
|
Phase 1
|
NCT07414953 |
Mar 2026 → Apr 2027 expected |
lung cancer |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05394818 |
Jul 2022 → Apr 2024 |
neoplasm |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05114759 |
Jan 2022 → Dec 2026 expected |
cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT06222879 |
Feb 2024 → Oct 2026 expected |
breast cancer |
Shandong Suncadia Medicine Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT06092268 |
Oct 2023 → Dec 2025 |
cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT06649331 |
Oct 2024 → Sep 2026 expected |
triple-negative breast carcinoma |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06465238 |
Jun 2024 → Jun 2026 overdue |
non-small cell lung carcinoma |
Henan Cancer Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05594095 |
Dec 2022 → Dec 2025 overdue |
female breast carcinoma, hormone receptor-positive breast cancer |
Fudan University |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03736863 |
Dec 2019 → Jun 2021 overdue |
esophageal cancer |
The First Affiliated Hospital of Zhengzhou University |
Recruiting
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT07183189 |
Oct 2025 → Nov 2032 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06671379 |
Nov 2024 → Dec 2026 expected |
non-small cell lung carcinoma |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Active not recruiting
|
No outcome recorded
|